Clear All
757 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Thioguanine Tabloid 40 mg Chemotherapy Antimetabolite Purine Analog Yes 1966 In Use
J7684 Triamcinolone Kenalog Aristocort 1 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1960 Jan 1, 2000 In Use
J9286 Glofitamab-gxbm Columvi 2.5mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct 1, 2017 In Use
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
J8530 Cyclophosphamide Cyclophosphamide oral 25 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 Jan 1, 1995 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
NA Leucovorin Calcium Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin 15 mg Ancillary Therapy Chemoprotective Antidote Yes 1952 Jan 1, 1997 In Use
J9285 Olaratumab Lartruvo 10 mg Immunotherapy Monoclonal Antibody PDGFR No 2016 Apr 1, 2017 In Use
J1447 Tbo-filgrastim Granix 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan 1, 2016 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
J9073 Cyclophosphamide (Dr Reddy's) Cyclophosphamide (Dr Reddy's) 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2020 Apr 17, 2024 In Use
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Apr 1, 1998 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Bispecific Antibody HER2, HER3 No 2024 Jul 9, 2025 In Use
J9297 Pemetrexed (Sandoz) Pemetrexed (Sandoz) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 Jul 9, 2025 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.